Vitamin D levels and lipid response to atorvastatin

International Journal of Endocrinology

Volumn 2010, Issue , 2010, Pages

  Pérez Castrillón, José Luis ^a,b   Abad Manteca, Laura ^a   Vega, Gemma ^a   Del Pino Montes, Javier ^b,c   De Luis, Daniel ^a   Dueňas Laita, Antonio ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b RETICEF ^*  (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77953312468     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2010/320721     Document Type: Article

References (23)

1. Baigent C., Keech A., Kearney P. M., Cholesterol Treatment Trialists (CTT) collaborators: efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 900056 participants in 14 randomised trials of statins The Lancet 2005 366 9493 1267 1278
2. Cannon C. P., Braunwald E., McCabe C. H., Intensive versus moderate lipid lowering with statins after acute coronary syndro (Pubitemid 38477774)
3. Fahrleitner A., Dobnig H., Obermosterer A., Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease Journal of General Internal Medicine 2002 17 9 633 639
4. Perez-Castrillon J. L., Vega G., Abad L., The effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease American Journal of Cardiology 2007 99 7 903 905 (Pubitemid 46483276)
5. Zittermann A., Schleithoff S. S., Koerfer R., Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Failure Reviews 2006 11 1 25 33 (Pubitemid 43986205)
6. Li Y. C., Vitamin D regulation of the renin-angiotensin system Journal of Cellular Biochemistry 2003 88 2 327 331 (Pubitemid 36119906)
7. Ferrario C. M., Strawn W. B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease American Journal of Cardiology 2006 98 1 121 128 (Pubitemid 43902687)
8. Thummel K. E., Brimer C., Yasuda K., Transcriptional control of intestinal cytochrome P4503A by 1alpha,25-dihydroxy vitamin D3 Molecular Pharmacology 2001 6 6 1399 1406 (Pubitemid 33144911)
9. Sans S., Fitzgerald A. P., Roys D., Conroy R., Graham I., Calibration de la tabla Score de riesgo vascular para Espana Revista Espaola de Cardiologa 2007 60 5 476 485
10. Norman A. W., From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health American Journal of Clinical Nutrition 2008 88 2 491S 499S
11. Kim D. H., Sabour S., Sagar U. N., Adams S., Whellan D. J., Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004) American Journal of Cardiology 2008 102 11 1540 1544
12. Lennernas H., Clinical pharmacokinetics of atorvastatin Clinical Pharmacokinetics 2003 42 13 1141 1160 (Pubitemid 37357650)
13. Holick M. F., Vitamin D deficiency The New England Journal of Medicine 2007 357 3 266 281
14. Gupta R. P., He Y. A., Patrick K. S., Halpert J. R., Bell N. H., CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis Journal of Clinical Endocrinology and Metabolism 2005 90 2 1210 1219 (Pubitemid 40279256)
15. Jacobsen W., Kuhn B., Soldner A., Lactonization is the critical first step in the disposition of the 3-hydroxy-3- methylglutarylCoA reductase inhibitor atorvastatin Drug Metabolism and Disposition 2000 28 11 1369 1378
16. Schwartz J. B., Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence Clinical Pharmacology and Therapeutics 2009 85 2 198 203
17. Defay R., Astruc M. E., Roussillon S., Descamps B., Crastes de Paulet A., DNA synthesis and 3-hydroxy-3-methylglutarylCoA reductase activity in PHA-stimulated human lymphocytes: a comparative study of the inhibitory effects of some oxyterols with special reference to side chain hydroxylated derivatives Biochemestry Biophysics Research Communication 1982 106 2 362 372 (Pubitemid 13214624)
18. Gupta A. K., Sexton R. C., Rudney H., Effect of vitamin D 3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells Journal of Lipid Research 1989 30 3 379 386 (Pubitemid 19082066)
19. Wilczek H., Sobra J., Justova V., Iatropathogenic effect of MEVACOR on vitamin D metabolism Casops Lekaru Ceskych 1989 128 40 1254 1256 (Pubitemid 19240450)
20. Wilzcek H., Sobra J., Ceska R., Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia Casops Lekaru Ceskych 1994 133 23 727 729 (Pubitemid 24380582)
21. Lips P., Vitamin D physiology Progress in Biophysics and Molecular Biology 2006 92 1 4 8 (Pubitemid 43831956)
22. Pilz S., Mrz W., Wellnitz B., Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography Journal of Clinical Endocrinology and Metabolism 2008 93 10 3927 3935
23. Lee J. H., OKeefe J. H., Bell D., Hensrud D. D., Holick M. F., Vitamin D deficiency. An important, common, and easily treatable cardiovascular risk factor? Journal of the American College of Cardiology 2008 52 24 1949 1956